

APPENDIX A**CLAIMS PENDING IN APPLICATION SERIAL NO. 09/822,110 AFTER
PRELIMINARY AMENDMENT**

1. (Original) An isolated peptide of from 9 to about 70 amino acids in length, said peptide comprising at least a first contiguous amino acid sequence according to any one of SEQ ID NO:3 through SEQ ID NO:76.
2. (Original) The isolated peptide of claim 1, of from 9 to about 60 amino acids in length.
3. (Original) The isolated peptide of claim 2, of from 9 to about 50 amino acids in length.
4. (Original) The isolated peptide of claim 3, of from 9 to about 40 amino acids in length.
5. (Original) The isolated peptide of claim 4, of from 9 to about 30 amino acids in length.
6. (Original) The isolated peptide of claim 5, of from 9 to about 20 amino acids in length.
7. (Amended) The isolated peptide of claim 1, said peptide comprising a first contiguous amino acid sequence selected from the group consisting of SEQ ID NO:3 and [SEQ ID NO:4] SEQ ID NO:5.

8. (Original) The isolated peptide of claim 1, said peptide consisting essentially of a contiguous amino acid sequence according to any one of SEQ ID NO:3 through SEQ ID NO:76.
9. (Original) The isolated peptide of claim 8, said peptide consisting of a contiguous amino acid sequence according to any one of SEQ ID NO:3 through SEQ ID NO:76.
10. (Original) The isolated peptide of claim 1, said peptide further comprising at least a second contiguous amino acid sequence according to any one of SEQ ID NO:3 to SEQ ID NO:76.
11. (Original) An isolated polypeptide consisting essentially of the amino acid sequence from position 1 to position 322 of SEQ ID NO:2.
12. (Original) The isolated polypeptide of claim 11, consisting of the amino acid sequence from position 1 to position 322 of SEQ ID NO:2.
-
32. (Amended) The isolated peptide of claim 1[, the polypeptide of claim 11, or the antibody or antigen-binding fragment of claim 13], further comprising at least a first detectable label.
33. (Amended) The [antibody or antigen-binding fragment isolated peptide of claim 32, wherein said at least a first label is a radiolabel, a chromogenic label, a fluorescent label

or a labelled secondary antibody that specifically binds to said peptide, said polypeptide, or said antibody.

34. (Amended) The [antibody or antigen-binding fragment] isolated peptide of claim 33, wherein said radiolabel comprises an ^3H , a ^{14}C , a ^{32}P , a ^{35}S , a ^{90}Y , a ^{99}Tc , an ^{125}I , or an ^{131}I label.
35. (Amended) The [antibody or antigen-binding fragment] isolated peptide of claim 33, wherein said chromogenic label comprises alkaline phosphatase, peroxidase, β -glucuronidase, β -D-glucosidase, β -D-galactosidase, urease, glucose oxidase/peroxidase, or galactose oxidase/peroxidase.
36. (Amended) The [antibody or antigen-binding fragment] isolated peptide of claim 33, wherein said fluorescent label comprises a fluorescent protein, fluorescein, rhodamine, or auramine.
37. (Amended) The [antibody or antigen-binding fragment] isolated peptide of claim 36, wherein said fluorescent protein comprises at least a first green fluorescent protein or at least a first humanized green fluorescent protein.

42. (Amended) A composition comprising:
- (a) an isolated peptide of from 9 to about 70 amino acids in length, said peptide comprising at least a first contiguous amino acid sequence according to any one of SEQ ID NO:3 through SEQ ID NO:76;
 - (b) an isolated polypeptide consisting essentially of the amino acid sequence from position 1 to position 322 of SEQ ID NO:2;
 - (c) a native, or biologically-active mammalian p33^{QIK} or p63^{Krs1} peptide or polypeptide; or
 - (d) a purified antibody, polyclonal antiserum, or antigen-binding fragment thereof, that is immunospecific for the peptide of (a), the polypeptide of (b), or the peptide of polypeptide of (c), or a hybridoma cell capable of producing said antibody] the isolated peptide of claim 1.
43. (Original) The composition of claim 42, further comprising at least a first pharmaceutically-acceptable excipient.
44. (Original) The composition of claim 42, further comprising at least a first immunostimulant or at least a first adjuvant.
45. (Original) The composition of claim 44, wherein said at least a first immunostimulant or said at least a first adjuvant is selected from the group consisting of a cytokine, a microsphere, Ribi Adjuvant, saponin, a microfluidized adjuvant, an immune stimulating complex, and an inactivated toxin.

46. (Original) The composition of claim 42, wherein said composition is formulated for parenteral, intravenous, intraperitoneal, subcutaneous, intranasal, transdermal, or oral administration to an animal.
47. (Original) The composition of claim 42, further comprising at least a first detection reagent.
48. (Original) The composition of claim 47, wherein said detection reagent comprises a radiolabel, a spin label, or a fluorogenic, chromogenic, or a chemiluminescent label.
49. (Original) The composition of claim 48, wherein said detection reagent specifically binds to a p33^{QIK} or p63^{Krs1} peptide or polypeptide, or to an antibody or an antigen binding fragment specific for a p33^{QIK} or p63^{Krs1} peptide or polypeptide.
50. (Amended) A kit comprising:
- (a) (i) an isolated peptide of from 9 to about 70 amino acids in length, said peptide comprising at least a first contiguous amino acid sequence according to any one of SEQ ID NO:3 through SEQ ID NO:76;
 - (ii) an isolated polypeptide consisting essentially of the amino acid sequence from position 1 to position 322 of SEQ ID NO:2;
 - (iii) a native, or biologically-active mammalian p33^{QIK} or p63^{Krs1} peptide or polypeptide; or

(iv) a purified antibody, polyclonal antiserum, or antigen-binding fragment thereof, that is immunospecific for the peptide of (i), the polypeptide of (ii), or the peptide of polypeptide of (iii), or a hybridoma cell capable of producing said antibody] the isolated peptide of claim 1[:] and

[(b)] instructions for using said kit.

51. (Original) The kit of claim 50, wherein said kit comprises at least one component for performing immunoprecipitation, a dot blot, an ELISA, an RIA, or a Western blot.

52. (Original) The kit of claim 50, wherein said kit comprises at least one component for immunoprecipitating a native or biologically-active mammalian p33^{QIK} or p63^{K₂₁} polypeptide from a sample.